Josh is a General Partner on NEA’s healthcare team leading their medtech/healthtech practice. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009. EndoMatrix, acquired by C.R. Bard in 1997 and TransVascular, acquired by Medtronic in 2003. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh currently serves on the board of directors for DOTS Devices, Eargo, ExploraMed, Intrinsic Therapeutics, NeoTract, Moximed, Nuelle, NC7, SetPoint Medical and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.
Anton is the CEO and a founding member of Moximed Inc. Prior to joining Moximed, Anton held a variety of R&D management positions at Abbott Vascular, a division of Abbott Laboratories, including Director of Research and Development for Coronary Technologies. In 2005, Anton was inducted into Abbott Laboratories Volweiler Society, a society established to recognize the company’s most distinguished scientists and engineers, and was awarded researcher of the year for outstanding contributions made to Abbott Laboratories vascular stent research. Anton started his career in medical devices at MedNova Ltd. in 1998, where he led the Carotid Stent Development Program. Anton is a prolific inventor, having more than 90 filed or issued US & International patents and multiple scientific publications. Dr. Clifford has holds a BSc and PhD in Materials Science from the University of Limerick, Ireland.
Mr. Croce comes to Moximed® Inc. after a 36-year career at Johnson & Johnson where he held a series of senior positions, culminating with 12 years as Company Group Chairman. He has been a Venture Partner/Venture Advisor with New Enterprise Associates (NEA) since February 2005. Previously, he was Worldwide Franchise Chairman of Cordis, a Johnson & Johnson company. Prior to that, he was Worldwide Franchise Chairman for Ethicon Endo-Surgery. Mr. Croce began his career with Johnson & Johnson in 1968 as a Sales Representative for Ortho Pharmaceuticals, where he was later named Vice President of Marketing. In 1985, Mr. Croce moved to McNeil Pharmaceutical as Vice President of Business Development and later transferred to Ethicon, Inc. as Group Vice President, where he remained until he was named President in 1990. In 1992 he was promoted to Worldwide President, Ethicon Endo-Surgery. Mr. Croce is a graduate of Central Missouri State University, where he earned undergraduate and graduate degrees.
Arthur Franken joined Gilde in 2001. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics, Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), ProQR Therapeutics (IPO on NASDAQ) and STAT-Diagnostica. He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ) and Pieris (IPO on NASDAQ).
He represents Gilde on the boards of Breath Therapeutics, Levicept, Moximed, STAT Diagnostica and Symphogen. He served as a board member for FlowCardia, MTM Laboratories and ProQR Therapeutics until the trade sales or IPO.
Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.
Mr. Lu, the founder of Biosensors International Group Ltd, was its chairman and CEO from its inception to 2008. He retained his leadership position as chairman of the Group since January 2008 until his recent retirement on 1 November 2016.
Mr. Lu has more than 30 years’ experience in the medical industry. Prior to starting Biosensors in 1990, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc. in Tokyo in 1978. In 1986, he participated in a management-led leveraged buyout of the division from Gould and he continued as president of the Asia-Pacific division through 1988. In the same year, Mr. Lu took the company to IPO in Nasdaq and it was subsequently sold to British Oxygen Corporation. He then served as president of Asia-Pacific with British Oxygen until 1990.
In addition to Biosensors, Mr. Lu is active in both international and local medical arenas as an entrepreneurial angel investor. Within the private equity arena, Mr. Lu is a General Partner at Majuven Pte Ltd; Foundry Singapore and a venture partner for medical sector at Vertex Venture Management Pte Ltd. With SPRING, Mr. Lu collaborates with Accuron Technologies Ltd (a wholly- owned subsidiary of Temasek) through the Sector Specific Accelerator program. He works closely with A*Star where he serves on the main committee of President’s Science and Technology Awards (PSTA) and he is a member of Health and Biomedical Sciences International Advisory Council (HBMS IAC). Mr. Lu has been serving on the Board of National Research Foundation (NRF) since February 2014 and most recently been appointed as the Chairman of NRF Audit Committee on 1 April 2017.
In academics, Mr. Lu has been a speaker at both Stanford University in USA as well as Singapore- Stanford Biodesign (SSB) where he conducts numerous speeches at both Palo Alto and Singapore campus. Mr. Lu holds a Bachelor of Science degree in Engineering from the University of California at Berkeley and a Master’s degree in Business Administration from the Thunderbird Graduate School of International Management in Arizona.
In over fifteen years of venture investing at Advent, Shahzad has been actively involved with numerous successful investments in Europe and the US in the biopharmaceutical, medical device, and diagnostics arenas. These include Algeta, Respivert, Biocartis, Powdermed and Versartis.
Shahzad came to Advent in 1999 with a strong background in science and clinical medicine. He gained invaluable experience at the London office of McKinsey & Company serving international clients in the Healthcare and Investment Banking sectors. Shahzad gained an MA in Physiological Sciences while at Oxford University and an MD from Cambridge University.
He then specialised in interventional cardiology while at the same time pursuing research interests in heart muscle disorders, both in the clinic and basic science laboratory.
Mr. Plain joined Morgenthaler Ventures in 2007 after more than 25 years in the life science industry, including co-founding eight medical device start-ups and directing the exits of four companies with a combined value well in excess of $1 billion. Mr. Plain is also the Vice Chairman of The Foundry, a medical device incubator based in Redwood City, California, where he co-founded Ardian, Cabochon Aesthetics, Cierra, Emphasys Medical, ForSight Labs, Satiety, Transcend and Xtent. He is a board member of Access Closure, Acclarent, and Moximed Inc. He served as President and CEO at Perclose, Inc. from 1993 to 2000, during which time he led the company to $100 million in sales and managed the company’s successful IPO and acquisition in 1999 by Abbott Laboratories for $650 million. He was Chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific for $200 million. He also served as a Director at TransVascular, Inc. until Medtronic acquired the company in 2003 for an undisclosed amount. Previously, Mr. Plain worked at Eli Lilly for 12 years in various management positions.
From 2008-2017 Kevin Sidow was President and Chief Executive Officer for Moximed Inc. Prior to that role, he was President and CEO for St. Francis Medical Technologies, Inc. Founded in 1997, St. Francis Medical Technologies was a privately held, venture funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc. Previously, Kevin was the Worldwide President of DePuy Inc., where he oversaw the global orthopedic, spine, trauma, and sports medicine businesses with annual revenue responsibility of over $3 billion. Kevin holds a BS in Accounting from West Virginia University.
Brigitte Smith has twenty years experience in venture capital, business strategy and start-up company operations. Brigitte has been investing and managing investments for GBS’s $450m of life science specialised venture capital funds since 1998. Brigitte is on the board of GBS portfolio companies Euthymics Inc, Elastagen Pty Ltd, ELS Pty Ltd and Moximed Inc.
Prior to founding GBS Brigitte worked in the US and Australia in operating roles with early stage technology based companies, and at Bain & Company as a strategic management consultant. Ms Smith has a B. Chem Eng (Honours) from the University of Melbourne, and as a Fulbright Scholar completed a MBA (Honours) from the Harvard Business School and a MALD from the Fletcher School of Law and Diplomacy, both in Boston, USA.